Despite a short week, healthcare dealmakers were busy at work, as Law360 counted at least four billion-dollar transactions involving names like BridgeBio and AstraZeneca. Here's a look at those deals and others.
Attorneys that helped guide this year’s string of biotech IPOs expect the fast pace of public offerings to continue.
Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.
Previous
Next
Despite a short week, healthcare dealmakers were busy at work, as Law360 counted at least four billion-dollar transactions involving names like BridgeBio and AstraZeneca. Here's a look at those deals and others.
Attorneys that helped guide this year’s string of biotech IPOs expect the fast pace of public offerings to continue.
Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.
-
July 08, 2026
Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.
-
July 08, 2026
The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.
-
July 07, 2026
A Texas federal jury has found that claims in four patents Invisalign maker Align Technology Inc. asserted against orthodontics company ClearCorrect were invalid, but the jurors also rejected ClearCorrect's antitrust claims against Align.
-
July 07, 2026
The Federal Circuit on Tuesday said it won't bring back claims in a pair of dental arch image analysis patents their owner accused Invisalign maker Align Technology Inc. of infringing, backing a lower court's finding that they were invalid.
-
July 06, 2026
Analytics company Clarivate PLC on Monday announced that it has agreed to sell its Life Sciences & Healthcare segment to investment firm Altaris LLC in a $600 million deal built by three law firms.
-
July 06, 2026
Summer is heating up in North Carolina Business Court with a slew of recent rulings, including one greenlighting a data breach class action brought by current and former workers who allege Charlotte-based Bojangles failed to guard their personal information from hackers.
-
July 06, 2026
Following several U.S. Supreme Court terms teeming with reversals and rebukes of lower appeals courts, the justices this term found fault less often with rulings by circuit judges, who are likely becoming better attuned to the conservative supermajority, attorneys say.
-
July 06, 2026
U.S. Supreme Court justices forged unusual alliances when they ruled a federal statute preempts claims Monsanto failed to warn consumers its Roundup weed killer may cause cancer. Oral arguments provided insights on the 7-2 outcome, highlighting issues the jurists were grappling with and showcasing rationales that found their way into the opinion.
-
July 06, 2026
When one of the U.S. Supreme Court's most talkative members suddenly struggled to speak, the atmosphere at oral arguments grew increasingly anxious — until the justice deadpanned that it was an advocate's golden opportunity to avoid a grilling.
-
July 06, 2026
Investors of Edwards Lifesciences Corp. have asked a California federal judge to grant the first green light to a $39 million settlement the parties reached to resolve claims that the medical technology company and its top brass made misleading statements about the growth of its leading artificial heart valve product.
-
July 02, 2026
The sharpest dissents this term often involved the president, and pitted conservative and liberal justices against each other on core constitutional issues and questions about the limits to executive power, with nearly a quarter of cases being decided squarely along ideological lines.
-
July 02, 2026
This U.S. Supreme Court term featured high-stakes oral arguments on issues including presidential power, immigration and voting regulations. Here's a look at the law firms that argued the most cases and how they fared.
-
July 02, 2026
The Supreme Court's conservative supermajority and President Donald Trump largely aligned this year on issues of executive power, resulting in a series of decisions that significantly expanded presidential authority.
-
July 02, 2026
Chubb, Liberty Mutual and Lloyd's of London units and other insurers urged a Pennsylvania federal court to find that they don't owe any additional coverage to bankrupt pharmaceutical company Endo International for the remainder of third-party payor opioid lawsuits filed against Endo during its 2017-2018 policy period.
-
July 02, 2026
Biotechnology firm United Therapeutics Corp. on Thursday revealed that it has agreed to buy a preclinical-stage biotech company focused on thymic cell therapies in a deal worth up to $300 million.
-
July 02, 2026
The U.S. Supreme Court's stark ideological divisions were on full display this term, particularly as it issued long-awaited rulings in the last few days of June. Here, Law360 dives into the numbers behind this court term.
-
July 01, 2026
French drugmaker Ipsen said Wednesday it has agreed to acquire Swiss biotechnology company Memo Therapeutics AG in a deal that could be worth more than €700 million ($796.6 million), expanding its pipeline of treatments for rare diseases.
-
June 30, 2026
It was deal after deal this past week, as Big Pharma continued to scoop up companies.
-
June 30, 2026
For attorneys defending healthcare clients hit with grand jury subpoenas and other enforcement actions investigating potential cases of fraud, cooperation with federal prosecutors is key.
-
June 30, 2026
A Massachusetts federal judge has permanently dismissed an investor suit alleging Zenas BioPharma hid how quickly it was spending money before its 2024 initial public offering, saying the company warned investors before the IPO that its drug-development costs were high and rising, and therefore did not have to provide a quarter-by-quarter spending breakdown.
-
June 30, 2026
The Federal Trade Commission has not sued over any healthcare provider mergers since President Donald Trump's return to the White House. Attorneys at the American Health Law Association annual meeting say that's not a signal that the agency is backing off.
-
June 30, 2026
Two former hospital workers urged a Colorado federal court to keep alive their proposed class and collective action alleging University of Colorado Health shorted hourly employees through a time-rounding policy and denied them required meal and rest breaks, saying their claims are sufficiently detailed to proceed.
-
June 29, 2026
A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most of their state-law antitrust claims to survive but dismissing their unjust enrichment claims.
-
June 29, 2026
A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.
-
June 26, 2026
A former chief executive officer of Washington-based Community Clinic Network has pled guilty to wire fraud in Washington federal court, admitting he drained almost $24.4 million from the healthcare company's coffers, most of which he lost in a series of poor investment decisions.